These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 18338947)

  • 1. Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes.
    Fortunato G; Calcagno G; Bresciamorra V; Salvatore E; Filla A; Capone S; Liguori R; Borelli S; Gentile I; Borrelli F; Borgia G; Sacchetti L
    J Interferon Cytokine Res; 2008 Mar; 28(3):141-52. PubMed ID: 18338947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous levels of mRNA for IFNs and IFN-related genes in hepatic biopsies of chronic HCV-infected and non-alcoholic steatohepatitis patients.
    Abbate I; Romano M; Longo R; Cappiello G; Lo Iacono O; Di Marco V; Paparella C; Spano A; Capobianchi MR
    J Med Virol; 2003 Aug; 70(4):581-7. PubMed ID: 12794720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection.
    Wietzke-Braun P; Maouzi AB; Mänhardt LB; Bickeböller H; Ramadori G; Mihm S
    Eur J Gastroenterol Hepatol; 2006 Sep; 18(9):991-7. PubMed ID: 16894313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver expression of proteins controlling interferon-mediated signalling as predictive factors in the response to therapy in patients with hepatitis C virus infection.
    Bautista D; Bermúdez-Silva FJ; Lasarte JJ; Rodriguez-Fonseca F; Baixeras E
    J Pathol; 2007 Nov; 213(3):347-55. PubMed ID: 17940994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus replication in mouse cells is restricted by IFN-dependent and -independent mechanisms.
    Nandakumar R; Finsterbusch K; Lipps C; Neumann B; Grashoff M; Nair S; Hochnadel I; Lienenklaus S; Wappler I; Steinmann E; Hauser H; Pietschmann T; Kröger A
    Gastroenterology; 2013 Dec; 145(6):1414-23.e1. PubMed ID: 23973921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An association study of functional polymorphic genes IRF-1, IFNGR-1, and IFN-γ with disease progression, aspartate aminotransferase, alanine aminotransferase, and viral load in chronic hepatitis B and C.
    Korachi M; Ceran N; Adaleti R; Nigdelioglu A; Sökmen M
    Int J Infect Dis; 2013 Jan; 17(1):e44-9. PubMed ID: 23040881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.
    Qashqari H; Al-Mars A; Chaudhary A; Abuzenadah A; Damanhouri G; Alqahtani M; Mahmoud M; El Sayed Zaki M; Fatima K; Qadri I
    Infect Genet Evol; 2013 Oct; 19():113-9. PubMed ID: 23831932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with repression of interferon regulatory factor-1.
    Zekri AR; Moharram RA; Mohamed WS; Bahnassy AA; Alam El-Din HM; Abo-Shadi MM; Zayed NA; El-Magzangy H; Abdel-Aziz AO; Esmat G
    Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):450-6. PubMed ID: 19858727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients.
    Lau DT; Fish PM; Sinha M; Owen DM; Lemon SM; Gale M
    Hepatology; 2008 Mar; 47(3):799-809. PubMed ID: 18203148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The detection of IRF-1 promoter polymorphisms and their possible contribution to T helper 1 response in chronic hepatitis C.
    Saito H; Tada S; Wakabayashi K; Nakamoto N; Takahashi M; Nakamura M; Ebinuma H; Ishii H
    J Interferon Cytokine Res; 2002 Jun; 22(6):693-700. PubMed ID: 12162881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of interferon regulatory factor-7 gene polymorphism with liver cirrhosis in chronic hepatitis C patients.
    Sermasathanasawadi R; Kato N; Muroyama R; Dharel N; Shao RX; Chang JH; Li CZ; Kawabe T; Omata M
    Liver Int; 2008 Jul; 28(6):798-806. PubMed ID: 18397234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.
    Wada M; Marusawa H; Yamada R; Nasu A; Osaki Y; Kudo M; Nabeshima M; Fukuda Y; Chiba T; Matsuda F
    J Viral Hepat; 2009 Jun; 16(6):388-96. PubMed ID: 19200137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered expression and activation of signal transducers and activators of transcription (STATs) in hepatitis C virus infection: in vivo and in vitro studies.
    Larrea E; Aldabe R; Molano E; Fernandez-Rodriguez CM; Ametzazurra A; Civeira MP; Prieto J
    Gut; 2006 Aug; 55(8):1188-96. PubMed ID: 16120756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of nod-like receptor protein-3 single nucleotide gene polymorphisms and expression with the susceptibility to relapsing-remitting multiple sclerosis.
    Imani D; Azimi A; Salehi Z; Rezaei N; Emamnejad R; Sadr M; Izad M
    Int J Immunogenet; 2018 Dec; 45(6):329-336. PubMed ID: 30264444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered interferon-alpha-signaling in natural killer cells from patients with chronic hepatitis C virus infection.
    Miyagi T; Takehara T; Nishio K; Shimizu S; Kohga K; Li W; Tatsumi T; Hiramatsu N; Kanto T; Hayashi N
    J Hepatol; 2010 Sep; 53(3):424-30. PubMed ID: 20554341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
    Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
    J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C.
    Wasmuth HE; Werth A; Mueller T; Berg T; Dietrich CG; Geier A; Gartung C; Lorenzen J; Matern S; Lammert F
    Hepatology; 2004 Aug; 40(2):327-34. PubMed ID: 15368437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response.
    Leyva L; Fernández O; Fedetz M; Blanco E; Fernández VE; Oliver B; León A; Pinto-Medel MJ; Mayorga C; Guerrero M; Luque G; Alcina A; Matesanz F
    J Neuroimmunol; 2005 Jun; 163(1-2):165-71. PubMed ID: 15885318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of TNF-beta polymorphism with disease severity among patients infected with hepatitis C virus.
    Goyal A; Kazim SN; Sakhuja P; Malhotra V; Arora N; Sarin SK
    J Med Virol; 2004 Jan; 72(1):60-5. PubMed ID: 14635012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signaling pathway but does not affect the activation of downstream IRF-1 or 561 gene.
    Basu A; Meyer K; Ray RB; Ray R
    Virology; 2001 Sep; 288(2):379-90. PubMed ID: 11601909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.